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Background: Pseudohypoaldosteronism type II (PHA II), also referred to as Gordon syndrome, is a rare renal tubular
disease that is inherited in an autosomal manner. Though mutations in WNK1 and WNK4 partially account for this
disorder, in 2012, 2 research groups showed that KLHL3 and CUL3 were the causative genes for PHA II. Here, we
firstly report on the Japanese child of PHA II caused by a mutation of CUL 3.
Case presentation: The patient was a 3-year-old Japanese girl having healthy unrelated parents. She was initially
observed to have hyperkalemia, hyperchloremia, metabolic acidosis, and hypertension. A close investigation led to
the diagnosis of PHA II, upon which abnormal findings of laboratory examinations and hypertension were
immediately normalized by administering thiazides. Genetic analysis of WNK1 and WNK4 revealed no mutations.
However, analysis of the CUL3 gene of the patient showed abnormal splicing caused by the modification of exon 9.
The patient is currently 17 years old and does not exhibit hypertension or any abnormal findings on laboratory
examination.
Conclusions: In this patient, CUL3 was found to play a fundamental role in the regulation of blood pressure,
potassium levels, and acid–base balance.
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Pseudohypoaldosteronism type II (PHA II), also referred
as Gordon syndrome, is a rare renal tubular disease that
is inherited in an autosomal manner [1]. Because thia-
zides are effective in the treatment of PHA II, a genetic
defect in the NaCl cotransporter (NCC), the target
transporter of thiazides, was thought to be the cause of
PHA II. However, in 2001, Wilson et al. first reported
that PHA II is caused by molecular abnormalities in 2
types of WNK (WNK; With No K [lysine]) genes, i.e.,
WNK1 and WNK4 [2]. Yang et al. confirmed that in
WNK4 knock-in mice, the NCC present in the cell
membranes of the luminal surface cells of the distal tu-
bule is excessively phosphorylated owing to a WNK4
mutation, resulting in hypertension due to abnormal
electrolyte/acid–base equilibrium and increased circulat-
ing blood volume [3]. However, a considerable number* Correspondence: tsujis@hirakata.kmu.ac.jp
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reproduction in any medium, provided the orof patients with PHA II did not exhibit any genetic de-
fect in WNKs. Recently, genetic defects in Kelch-like 3
(KLHL3) or Cullin 3 (CUL 3) were also reported to cause
PHA II [4].
Here, we present the first case, to our knowledge, of
PHA II caused by a mutation of CUL3, diagnosed in a
3-year-old Japanese child.
Case presentation
Direct sequencing of DNA and mRNA and splicing assay
Genomic DNA and RNA were extracted from peripheral
blood lymphocytes by using a QIAamp DNA Blood Midi
Kit (Qiagen, Venlo, The Netherlands) and Tempus™ Spin
RNA isolation Kit (Applied Biosystems, Foster City, CA,
USA), respectively. The mRNA was reverse-transcribed
with oligo(dT) primer (Omniscript RT Kit, Qiagen, Venlo,
The Netherlands). A 633-bp segment of the CUL3 gene
was amplified by polymerase chain reaction (PCR)
(Primers: forward, 5′-TACGGAATAGAATTCCACTC-3′;
reverse, 5′-CTCCATGAATGTATCCTGAC-3′) from gen-
omic DNA. A 561-bp segment (390 bp, if exon 9 wasd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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AGGGAGCAAGGTAAAGCTC-3′; reverse, 5′-GCACCC
GGACTGTAAGATCA-3′) from the cDNA. The PCR
products were verified by sequencing. The ethics com-
mittee of Saiseikai Noe Hospital approved this study
after consent from the patient’s guardian was obtained.
Case report
The patient was a 3-year-old Japanese girl with healthy
unrelated parents. Her perinatal history and past medical
history were unremarkable. She was observed to have
hyperkalemia, hyperchloremia, metabolic acidosis, and
hypertension, when she was admitted to our hospital for
the treatment of croup syndrome. An initial physical
examination revealed normal growth, with a height of
95.5 cm (+0.3 standard deviation [SD]) and a body
weight of 14.0 kg (+0.2 SD). The patient’s development
was also normal. Her body temperature was 36.4°C.
Chest auscultation revealed normal breathing sounds
and a regular heart beat without murmurs. Examination
of the patient’s blood and blood pressure revealed
hyperkalemia (6.8 mEq/L), hyperchloremia (112 mEq/L),
metabolic acidosis (pH, 7.248; HCO3
- , 12.6 mEq/L), and
hypertension (124/30 mmHg). The plasma renin activity
(0.2 ng∙ml-1∙h-1) and plasma aldosterone concentration
(25 pg/ml) were also low. A closer investigation led to
the diagnosis of PHA II, and abnormal findings on la-
boratory examinations and hypertension were promptlyFigure 1 Result of direct sequencing of DNA and mRNA and splicing
the patient (PT), the last guanine (G) of exon 9 of the Cullin 3 in the wild ty
mRNA in the index patient. In the wild type (WT), exon 8 is followed by ex
as exon 9 is skipped in the patient (PT). (c) Reverse Transcription Polymerase C
Cullin 3 mRNA demonstrated a smaller molecular weight band (390 bp) only
type (WT). The smaller band is considered a product of the skipping of exon 9normalized by the administration of thiazides. Subse-
quent genetic analysis of WNK1 and WNK4 revealed no
mutations. The CUL3 gene of the patient, her parents,
and her younger brother were analyzed in 2013, based
on the report by Boyden et al. [4]. Abnormal splicing
caused by modification of exon 9 was detected only in
the patient (Figure 1a). The skipping of exon 9 at the
mRNA level was further confirmed by sequence analysis
(Figure 1b) and reverse-transcription PCR (Figure 1c).
Because a mutation of CUL3 and manifestation of PHA
II were not observed in the family members of the pa-
tient, in this case, the mutation was considered to be de
novo. The patient is currently 17 years old and is healthy,
with no hypertension or abnormal findings on laboratory
examinations. The most recently recorded height and
body weight of the patient were 155.6 cm (−0.4 SD) and
52.6 kg (−0.1 SD), respectively.
Conclusions
Monogenic disorders such as PHA II give the opportun-
ity to observe the clinical effects of a mutated gene.
PHA II attracts special attention because its symptoms
(hypertension, hyperkalemia, and acidosis) are usually
caused by renal insufficiency, which is a relatively com-
mon cause of elevated blood pressure. PHA II is caused by
the loss of WNK4-mediated tonic inhibition of thiazide-
sensitive NCC in the distal convoluted tubule, by a kinase-
dependent mechanism, due to loss-of-function mutationsassay. (a) Sequence analysis of Cullin 3 DNA in the index patient. In
pe (WT) was displaced to cytosine (C). (b) Sequence analysis of Cullin 3
on 9 in Cullin 3 mRNA. In contrast, exon 10 is present just after exon 8
hain Reaction (RT-PCR) of Cullin 3 mRNA in the index patient. RT-PCR of
in the patient (PT) in addition to the band (561bp) observed in the wild
.
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Though mutations in WNK1 and WNK4 are the cause of
PHAII in some patients, recent successive studies have
shown that KLHL3 and CUL3 are also causative genes for
PHA II [4,5]. The CUL3 protein forms a complex with
KLHL3 proteins, which then functions as a ubiquitin lig-
ase. However, the exact role of these genes in PHAII is
currently unknown. Recently, some groups reported that
an interaction of KLHL3 with CUL3 and WNK4 induced
WNK4 ubiquitination and reduced the WNK4 protein
level, while a reduction in the interaction between KLHL3
and WNK4 attenuated the ubiquitination of WNK4,
resulting in an increased level of the WNK4 protein [6-8].
The genotype-phenotype correlation in PHA II remains
unknown, because only a few descriptions of PHA II in
childhood have been reported [9-11]. Interestingly, Boyden
et al. [4] reported that the onset of PHA II caused by
CUL3 mutation is earlier and the disease is more severe
than is PHA II caused by KLHL3 recessive, KLHL3 dom-
inant, WNK4, and WNK1 mutations. In agreement with
their report, the patient in the present case was diagnosed
with evident hyperkalemic metabolic acidosis and hyper-
tension at the early age of 3 years. It is noteworthy that
despite the severity of the PHA II symptoms, administra-
tion of thiazides alone was sufficient to ensure normal de-
velopment and growth of the patient.
This case demonstrates that KLHL3/CUL3 plays a fun-
damental role in the regulation of blood pressure, potas-
sium levels, and acid–base balance.
Consent
Written informed consent was obtained from the pa-
tient for publication of this case report. A copy of the
written consent is available for review by the Editor of
this journal.
Abbreviations
PHA II: Pseudohypoaldosteronism type II; NCC: NaCl cotransporter;
KLHL3: Kelch-like 3; CUL 3: Cullin 3; PCR: Polymerase chain reaction.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ST and TK performed the literature search and drafted the manuscript. MY,
GU and RT were also treating physicians for the patient. KI and MC carried
out the molecular genetic studies and participated in the sequence
alignmen. SU and KK conceived of the study and helped to draft the
manuscript. All authors read and approved the final manuscript.
Acknowledgement
This study was partly supported by the Mami Mizutani Foundation.
Author details
1Department of Pediatrics, Kansai Medical University, 2-5-1 Shin- machi,
Hirakata- shi, Osaka 573 1010, Japan. 2Department of Pediatrics, Saiseikai Noe
Hospital, Osaka, Japan. 3Department of Pediatrics, Unishi Clinic, Osaka, Japan.
4Department of Nephrology, Graduate School of Medical and Dental
Sciences, Tokyo Medical and Dental University, Tokyo, Japan.Received: 11 April 2013 Accepted: 30 July 2013
Published: 31 July 2013
References
1. Gordon RD, Geddes RA, Pawsey CG, O'Halloran MW: Hypertension and
severe hyperkalaemia associated with suppression of renin and
aldosterone and completely reversed by dietary sodium restriction.
Australas Ann Med 1970, 19(4):287–294.
2. Wilson FH, Disse-Nicodeme S, Choate KA, Ishikawa K, Nelson-Williams C,
Desitter I, Gunel M, Milford DV, Lipkin GW, Achard JM, et al: Human
hypertension caused by mutations in WNK kinases. Science 2001,
293(5532):1107–1112.
3. Yang SS, Morimoto T, Rai T, Chiga M, Sohara E, Ohno M, Uchida K, Lin SH,
Moriguchi T, Shibuya H, et al: Molecular pathogenesis of
pseudohypoaldosteronism type II: generation and analysis of a Wnk4
(D561A/+) knockin mouse model. Cell Metab 2007, 5(5):331–344.
4. Boyden LM, Choi M, Choate KA, Nelson-Williams CJ, Farhi A, Toka HR,
Tikhonova IR, Bjornson R, Mane SM, Colussi G, et al: Mutations in kelch-like
3 and cullin 3 cause hypertension and electrolyte abnormalities. Nature
2012, 482(7383):98–102.
5. Louis-Dit-Picard H, Barc J, Trujillano D, Miserey-Lenkei S, Bouatia-Naji N,
Pylypenko O, Beaurain G, Bonnefond A, Sand O, Simian C, et al: KLHL3
mutations cause familial hyperkalemic hypertension by impairing ion
transport in the distal nephron. Nat Genet 2012, 44(4):456–460. S451-453.
6. Wakabayashi M, Mori T, Isobe K, Sohara E, Susa K, Araki Y, Chiga M, Kikuchi
E, Nomura N, Mori Y, et al: Impaired KLHL3-Mediated Ubiquitination of
WNK4 Causes Human Hypertension. Cell Rep 2013, 3(3):858–868.
7. Ohta A, Schumacher FR, Mehellou Y, Johnson C, Knebel A, Macartney TJ,
Wood NT, Alessi DR, Kurz T: The CUL3-KLHL3 E3 ligase complex mutated
in Gordon's hypertension syndrome interacts with and ubiquitylates
WNK isoforms: disease-causing mutations in KLHL3 and WNK4 disrupt
interaction. Biochem J 2013, 451(1):111–122.
8. Shibata S, Zhang J, Puthumana J, Stone KL, Lifton RP: Kelch-like 3 and
Cullin 3 regulate electrolyte homeostasis via ubiquitination and
degradation of WNK4. Proc Natl Acad Sci USA 2013, 110(19):7838–7843.
9. Mayan H, Vered I, Mouallem M, Tzadok-Witkon M, Pauzner R, Farfel Z:
Pseudohypoaldosteronism type II: marked sensitivity to thiazides,
hypercalciuria, normomagnesemia, and low bone mineral density. J Clin
Endocrinol Metab 2002, 87(7):3248–3254.
10. Mayan H, Munter G, Shaharabany M, Mouallem M, Pauzner R, Holtzman EJ,
Farfel Z: Hypercalciuria in familial hyperkalemia and hypertension
accompanies hyperkalemia and precedes hypertension: description of a
large family with the Q565E WNK4 mutation. J Clin Endocrinol Metab
2004, 89(8):4025–4030.
11. Mayan H, Melnikov S, Novikov I, Holtzman EJ, Farfel Z: Familial
hyperkalemia and hypertension: pathogenetic insights based on lithium
clearance. J Clin Endocrinol Metab 2009, 94(8):3010–3016.
doi:10.1186/1471-2369-14-166
Cite this article as: Tsuji et al.: A young child with
pseudohypoaldosteronism type II by a mutation of Cullin 3. BMC
Nephrology 2013 14:166.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
